抗菌药物敏感性试验 药敏试验 抗生素耐药细菌

细菌与科学:一场对抗耐药性的竞赛

执行摘要

抗菌药物耐药性位列世界卫生组织全球十大健康威胁之一,预计到2050年,耐药性感染每年将导致多达1000万人死亡。

耐药性的产生源于多种内在和获得性机制,包括细胞壁通透性改变、外排泵作用、基因突变以及药物的酶促降解。

受生物膜、革兰氏阴性菌防御机制、投资回报率低以及10至15年的研发周期限制,新型抗生素的开发速度严重滞后于耐药性的演变。

细菌疫苗、抗菌肽、噬菌体和严紧反应抑制等替代方案,为超越传统小分子抗生素提供了有前景的路径。

先进的材料解决方案和新兴的人工智能驱动发现方法,有望缩短研发周期并减少对传统抗生素的依赖。2205年8月,麻省理工学院的研究人员报告称,他们利用生成式人工智能发明了针对耐药性淋病和金黄色葡萄球菌的抗生素。

2026年5月更新:美国食品药品监督管理局(FDA)批准了Zaynich,这是一种通过同时攻击三种细菌蛋白而非单一靶点来抵抗细菌适应性的抗生素,为临床医生治疗此前几乎无药可治的耐药性感染提供了新的选择。

‍

世界卫生组织(WHO)将经过正规治疗后仍未被杀灭或灭活的微生物定义为“耐药”,耐药微生物的增加是由多种因素共同导致的。根据美国疾病控制与预防中心(CDC)的数据,每年发生超过280万例抗生素耐药性细菌感染,导致超过35,000人死亡。令人担忧的是,世界银行的预测显示,到2050年,这一数字可能增加到每年1000万人死亡。

因此,世界卫生组织已将抗菌药物耐药性列为全球十大主要健康问题之一,迫切需要新的解决方案。

抗生素耐药性是由多种因素导致的

抗生素耐药性可由内在和获得性因素共同导致。内在因素包括细胞壁通透性、药物靶点修饰、外排泵激活以及抗生素的酶促降解。获得性耐药则源于细菌基因组中获得的新遗传物质或突变,从而介导其生存。

 

Four common antimicrobial resistance mechanisms
图1. 细菌中常见的四种抗菌药物耐药机制,可源于突变或耐药质粒。A. 细胞壁通透性改变,减少或阻止抗菌药物进入细菌。B. 药物靶点的修饰或缺失,降低药物结合能力,导致药效下降。C. 响应抗菌药物治疗而表达的外排泵,在药物发挥作用前将其排出。D. 抗生素的酶促降解,使其失去药效。

对新型抗菌治疗的需求

抗生素涵盖了许多不同的类别。每种抗生素都根据其结构以及在体内对抗细菌的方式进行分类。

Antibiotic class Structure
Aminoglycosides (e.g., streptomycin, 57-92-1) Aminoglycosides-image1
Beta-lactams (e.g., penicillin, 61-33-6) Beta-lactams-image2
Sulfonamides (e.g., sulfadiazine, 68-35-9)   Sulfonamides-image3
Amphenicols (e.g., chloramphenicol, 56-75-7) Amphenicols-image4
Polymyxins (e.g., polymixin B, 1404-26-8) Polymyxins-image5
Tetracyclines (e.g., tetracycline, 60-54-8) Tetracyclines-image6
Macrolides (e.g., clarithromycin, 81103-11-9) Macrolides-image7
Pyrimidines (e.g., sulfadiazine  68-35-9)  sulfadiazine
Rifamycins (e.g., rifampicin, 13292-46-1)  Rifamycins-image9
Quinolones and fluoroquinolones (e.g., nalidixic acid, 389-08-2) Quinolones-image10
Streptogramins (e.g., quinupristin, 120138-50-3) Streptogramins-image11
Lincosamides (e.g., lincomycin, 154-21-2) Lincosamides-image12
Pleuromutilins (e.g., lefamulin, 1061337-51-6) Pleuromutilins-image13
Oxazolidinones (e.g., linezolid, 165800-03-3) Oxazolidinones-image14

​表 1. 各类抗生素。

尽管已有成熟的治疗方案,但许多感染对现有的抗生素治疗产生了耐药性。加之相关死亡人数预计呈上升趋势,我们迫切需要重新审视应对细菌感染的方式。

新型抗菌药物面临的挑战

虽然抗菌药物耐药性的增加是由多种因素导致的,但新治疗方案的开发速度滞后于耐药性的演变速度,进一步加剧了这一问题。

这一点从抗菌药物耐药性相关的期刊发表数量与专利申请的低比例对比中显而易见(图 2)。这表明学术界研究人员在开发新型抗菌药物方面正发挥着越来越重要的作用,而这些研究成果必须转化为可商用的疗法。

The number of journal and patent publications per year in the antimicrobial research
图 2。 过去十年(2012–2022 年)抗菌药物研究领域的年度期刊发表量与专利申请量(分别以蓝色和黄色柱状图表示)。

造成抗菌药物开发困难的原因有多种。除了微生物用于抵抗抗菌药物的多种先天或获得性机制(图 1)外,还有更广泛的因素阻碍了开发进程(图 3)。

细菌对抗菌药物的耐受能力,加上高昂的开发成本和漫长的周期(图 3),导致尽管需求迫切,但近几十年来上市的抗生素寥寥无几。

Biofilms

Growing in a biofilm, or a layer of cells, allows bacteria to withstand antibiotic penetration. Biofilms can grow on catheters, pacemakers, joint prostheses, dentures, contact lenses, prosthetic heart valves, and implants. Growing in a biofilm, or a layer of cells, allows bacteria to withstand antibiotic penetration. Biofilms can grow on catheters, pacemakers, joint prostheses, dentures, contact lenses, prosthetic heart valves, and implants.

Outer layer of Gram-negative bacteria

Gram-negative bacteria are naturally resistant to various drugs that affect Gram-positive species due to their bilayer, outer membrane that is impenetrable to many drugs.

Return on investment

Low success rate of candidate molecules in combination with lesser return on investment are major challenges.

Timelines

It can take 10-15 years between initial molecule discovery to having a viable antibiotic reach the market.

 Figure 3. Factors that can confound antimicrobial development.

传统抗生素的替代方案

将新型抗生素推向市场是一项耗时的挑战(图 3),因此,替代方案正助力于对抗抗菌药物耐药性。

Stringent response inhibition Long-term survival of bacteria in the host, often asymptomatically, can lead to reactivation and reinfection. These long-surviving bacteria are called “persister bacteria.” Stringent response is a mechanism through which bacteria counter extreme starvation, which is thought to contribute to the development of persistent infection. Inhibiting this process could lead to greater bacterial susceptibility to antibiotics.
Bacterial vaccines Preventing bacterial infections through vaccines leads to decreased antibiotic consumption and is likely to help with antibiotic resistance. A 2021 WHO report provided details of >60 and >90 vaccines in clinical and preclinical development, respectively.
Antimicrobial peptides Antimicrobial peptides are gaining popularity as alternatives to small-molecule antibiotics. They are typically short (<100 amino acids) peptides with a broad spectrum of antimicrobial activity. According to the Antimicrobial Peptide Database, there are over 3,000 antimicrobial peptides as of November 2022.
Glycopeptides Glycopeptides display antibacterial activity primarily against Gram-positive bacteria by inhibiting cell wall biosynthesis. Commonly used drugs in this group are vancomycin, teicoplanin, telavancin, dalbavancin, and oritavancin, but many new options are being developed, studied, and optimized.
Lipopeptides and lipoglycopeptides Daptomycin is the only lipopeptide currently used against Gram-positive bacteria and functions by disrupting the bacterial cell membrane. The antibacterial effect observed appears dependent on the presence of and binding with calcium. Due to their large size, they are poorly absorbed when taken orally and tend to be administered intravenously.
Bacteriophages Bacteriophages are viruses capable of infecting the bacteria cell and killing them by injecting viral DNA. The virus replicates within the cell and causes cell lysis as the replicas are released to find a new bacterial cell to infect. However, challenges still must be addressed to make bacteriophage therapy more viable, including poor in vivo efficacy for targeting bacterial species in the gut following oral administration.

Table 2. Alternatives to conventional antibiotics

抗菌药物的未来

通过材料实现的增强型药物递送方法,可以提供局部、持久且受刺激响应的抗菌活性。除了传统的给药方式外,还有多种途径可以实现抗菌药物的递送。植入物和导管等医疗器械可能成为感染源,而使用抗菌材料则有望预防此类感染。同样,在高频接触表面使用抗菌涂层可以减少微生物的传播,并降低清洁需求。

Hydrogels

Used together with antibiotics for drug delivery and wound healing. Hydrogels act in situ while being exposed to bodily cells and fluids to enable diffusible or gel-bound antibiotic agents such as antimicrobial peptides to be administered.

Nanoparticles

The small size of nanoparticles makes it easy for them to deliver drugs effectively. Surface modification can be used to tailor them for specific targets and locations, and the surface chemistry and composition control the timing of activity, drug release, and duration of action.

Composites

Composites use multiple materials together and are used for medical devices such as dental implants. The variety of materials capable of exerting antimicrobial activity have proven efficacy in both treating and preventing infection and transmission.

Films or coatings

Reducing the ability of medical devices to transmit infection would be an effective way to improve the health and survival of hospital patients. The ability to harness UV or visible light and generate reactive oxygen species that prevent microorganisms from adhering are two examples of effective films and coatings.

Scaffolds and implants

Useful for wound and bone healing, these typically have a high surface area-to-volume ratio and are more persistent than hydrogels. Implants with cationic polymers, copper nanoparticles, or nitric oxide-releasing agents have shown promising efficacy.

Figure 4. Materials and solutions that can reduce antibiotic usage

人工智能(AI)的进步加速了抗菌药物的开发,利用算法识别潜在的新分子。尽管相关期刊发表数量稳步增长,但专利申请量并未出现相应的激增,这表明大多数抗菌药物的 AI 研究仍处于学术阶段(图 5)。

The rapid growth of publications and patents for antimicrobial development
图 5。涉及 AI 方法的抗菌药物开发在期刊发表(蓝色)和专利申请(黄色)方面的快速增长。

多重耐药细菌的兴起对人类健康构成了严峻威胁,开发新型抗生素和抗菌材料刻不容缓。AI 的广泛应用尚处于起步阶段,但它在简化流程和缩短未来研发周期方面展现出巨大潜力。如需了解 AI 对化学领域的影响,请参阅我们的 洞察报告,了解 大语言模型 的兴起,以及 生物材料 如何在各种新方法中应用于治疗领域。

常见问题解答

什么是抗生素耐药性?

细菌产生抗生素耐药性的原因是什么?

抗生素的主要类别有哪些?

传统抗生素有哪些替代方案?

相关 CAS 洞察

戴着手套的双手捧着一枚金质诺贝尔奖章。

诺贝尔奖得主

超临界二氧化碳:一种可用于制药、发电等领域的绿色溶剂

基因组规模的生成式设计:AI语言模型编写了什么,以及为何有效 

获取全新视角,助您加速实现目标,直接发送至您的收件箱。